These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 11128658

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Anti-cyclic citrullinated peptide antibodies as a diagnostic test for rheumatoid arthritis].
    Orbach H, Shoenfeld Y.
    Harefuah; 2003 Mar; 142(3):182-5, 239. PubMed ID: 12696470
    [Abstract] [Full Text] [Related]

  • 23. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test?
    Panchagnula R, Rajiv SR, Prakash J, Chandrashekara S, Suresh KP.
    J Clin Rheumatol; 2006 Aug; 12(4):172-5. PubMed ID: 16891919
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.
    Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM.
    Scand J Rheumatol; 2008 Aug; 37(5):329-36. PubMed ID: 18666028
    [Abstract] [Full Text] [Related]

  • 27. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
    Goëb V, Dieudé P, Daveau R, Thomas-L'otellier M, Jouen F, Hau F, Boumier P, Tron F, Gilbert D, Fardellone P, Cornélis F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
    [Abstract] [Full Text] [Related]

  • 28. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M.
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [Abstract] [Full Text] [Related]

  • 29. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA.
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [Abstract] [Full Text] [Related]

  • 30. Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis.
    Bas S, Perneger TV, Mikhnevitch E, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA.
    Rheumatology (Oxford); 2000 Oct; 39(10):1082-8. PubMed ID: 11035127
    [Abstract] [Full Text] [Related]

  • 31. Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance.
    Gupta B, Raghav SK, Agrawal C, Chaturvedi VP, Das RH, Das HR.
    J Autoimmun; 2006 Sep; 27(2):125-33. PubMed ID: 16904869
    [Abstract] [Full Text] [Related]

  • 32. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
    de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF.
    Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
    [Abstract] [Full Text] [Related]

  • 33. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K.
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [Abstract] [Full Text] [Related]

  • 34. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.
    Sihvonen S, Korpela M, Mustila A, Mustonen J.
    J Rheumatol; 2005 Nov; 32(11):2089-94. PubMed ID: 16265684
    [Abstract] [Full Text] [Related]

  • 35. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis.
    Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher HR, El-Gabalawy HS.
    Rheumatology (Oxford); 2005 Nov; 44(11):1433-41. PubMed ID: 16091399
    [Abstract] [Full Text] [Related]

  • 36. Diagnostic value of antibodies to filaggrin in rheumatoid arthritis.
    Slack SL, Mannik M, Dale BA.
    J Rheumatol; 1998 May; 25(5):847-51. PubMed ID: 9598878
    [Abstract] [Full Text] [Related]

  • 37. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [Abstract] [Full Text] [Related]

  • 38. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis.
    Lin P, Bhullar SS, Tessler HH, Goldstein DA.
    Am J Ophthalmol; 2008 Mar; 145(3):463-471. PubMed ID: 18061135
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.